- Azelis reported first-half revenue at €2.16 billion, close to the estimated €2.17 billion.
- The company’s adjusted EBITA came in at €234.5 million, slightly below the expected €239 million.
- Earnings per share (EPS) were reported at €0.34, which was below the estimate of €0.43.
- Free cash flow was significantly lower than expected, at €151.2 million compared to the forecasted €282.1 million.
- Despite global trade and geopolitical uncertainties, Azelis is confident in its strategic approach to capitalize on industry volatility.
- Analyst ratings include 14 buy recommendations and 2 holds, with no sell recommendations.
A look at Azelis Group NV Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts are cautiously optimistic about the long-term outlook for Azelis Group NV, a company that wholesales and distributes chemicals worldwide. With a Smartkarma Smart Score of 3 for both Value and Growth, the company is seen as having solid potential for future value appreciation and sustainable growth. Additionally, its Resilience score of 3 suggests that the company is relatively stable in the face of market volatility, providing a sense of security for investors.
However, Azelis Group NV falls slightly short in terms of Dividend and Momentum, with scores of 2 for both factors. This indicates that the company may have room for improvement in terms of dividend payouts and the speed at which its stock price is expected to rise. Overall, while there are areas for enhancement, Azelis Group NV‘s overall outlook remains positive, offering investors a balanced mix of value, growth potential, and stability in the volatile chemical distribution market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
